Novo Nordisk shares rebound after FDA warning on illegal weight-loss drugs: Copycat maker Hims and Hers responds
Novo Nordisk shares rose by more than 5% after scrutiny of Hims & Hers Health's compounded semaglutide pill following an FDA warning. Hims plans to offer the drug at $49, while Novo's brand costs $149.
Novo Nordisk shares rose by more than 5% after scrutiny of Hims & Hers Health's compounded semaglutide pill following an FDA warning. Hims plans to offer the drug at $49, while Novo's brand costs $149.
What's Your Reaction?
DDP Editor
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
